Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

UK doctors look back at real-world use of new VWD drug

NCT ID NCT06433778

Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at medical records of 34 adults with von Willebrand disease (VWD) in the UK who received a newer treatment called vonicog alfa (rVWF). The goal was to see how well it controlled bleeding and was used during surgeries in real-world settings. No new treatments or tests were given; researchers simply collected existing data from routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

34 people

The number who actually took part.

Started

Dec 2021

Finished

Oct 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants who have been diagnosed with congenital VWD and were prescribed rVWF in UK.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Adults (aged 18 or over at time of first administration of rVWF) who have provided informed consent and used rVWF within its licensed indication. * Participants who have been diagnosed with congenital von Willebrand disease. * Confirmed instance of * at least one bleed (either a new bleed or ongoing bleed treated under a treatment switch) treated on-demand with rVWF between 01-Oct-2020 and 30-Jun- 2022 and/or * treatment to prevent and treat surgical bleeds with rVWF between 01-Oct-2020 and 30-Jun-2022 Exclusion criteria: * Participants who were aged 17 years or less at the time of the first administration of rVWF. * Participants who have been diagnosed with any other bleeding disorders or factor deficiencies including acquired von Willebrand disease. * Participants with neutralising antibodies/inhibitors to VWF. * Participants participation in a clinical trial of an investigational medical product during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Von Willebrand disease (VWD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

von Willebrand disease (hereditary or acquired)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Von Willebrand disease (VWD)

Contacts and locations

Locations

  • Imperial College Healthcare

    London, W2 1NY, United Kingdom

  • Leeds Teaching Hospital

    Leeds, LS9 7TF, United Kingdom

  • Liverpool University Hospital

    Liverpool, L7 8XP, United Kingdom

  • Manchester University

    Manchester, M13 9WL, United Kingdom

  • Oxford University Hospital

    Oxford, OX3 9DU, United Kingdom

  • Royal Free London

    London, NW3 2QG, United Kingdom

  • University Hospitals Birmingham

    Birmingham, B15 2GW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.